Malaysian Genomics Resource Cash Flow Conversion Efficiency

Latest as of June 2026: 0.053x

Malaysian Genomics Resource cash flow conversion efficiency. Based on the latest financial reports, Malaysian Genomics Resource (0155) has a cash flow conversion efficiency ratio of 0.053x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (RM1.01 Million ≈ $253.08K USD) by net assets (RM18.88 Million ≈ $4.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Malaysian Genomics Resource for the company's overall valuation and market capitalisation.

Cash Flow Conversion Efficiency of Malaysian Genomics Resource (2015–2026)

Cash flow conversion efficiency of Malaysian Genomics Resource from 2015 to 2026. This chart illustrates how Malaysian Genomics Resource's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Malaysian Genomics Resource (0155) stock price for real-time trading data and today's change.

Malaysian Genomics Resource Cash Flow Conversion Ratio Explained

Malaysian Genomics Resource cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Malaysian Genomics Resource Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Malaysian Genomics Resource ranked by their cash flow conversion efficiency. Review cash generation quality of Malaysian Genomics Resource to assess how much free cash flow the company generates relative to operating cash flow.

Company	Cash Flow Conversion Efficiency
OpTeam S.A. WAR:OPM	-0.102x
Medience Co. LTD KQ:014100	-0.019x
iZafe Group AB Series B ST:IZAFE-B	-0.190x
Medicon Hellas S.A. AT:MEDIC	0.008x
Little Green Pharma Ltd AU:LGP	0.003x
Spire Healthcare Group Plc LSE:SPI	0.151x
Baillie Gifford US Growth Trust PLC LSE:USA	-0.004x
Azio AI Holdings, Inc. NASDAQ:AZIO	0.435x

Annual Cash Flow Conversion Efficiency for Malaysian Genomics Resource (2015–2026)

The table below shows the annual cash flow conversion efficiency of Malaysian Genomics Resource from 2015 to 2026. Also see 0155 total assets for a full breakdown of the balance sheet.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2026-06-30	RM14.78 Million ≈ $3.71 Million	RM1.10 Million ≈ $277.42K	0.075x	+282.15%
2025-06-30	RM18.16 Million ≈ $4.56 Million	RM-744.97K ≈ $-187.04K	-0.041x	+96.33%
2024-06-30	RM22.35 Million ≈ $5.61 Million	RM-24.97 Million ≈ $-6.27 Million	-1.117x	-35.64%
2023-06-30	RM26.79 Million ≈ $6.73 Million	RM-22.07 Million ≈ $-5.54 Million	-0.824x	-53707.58%
2022-06-30	RM37.05 Million ≈ $9.30 Million	RM56.92K ≈ $14.29K	0.002x	+101.05%
2021-06-30	RM17.93 Million ≈ $4.50 Million	RM-2.64 Million ≈ $-661.90K	-0.147x	-112.93%
2020-06-30	RM10.26 Million ≈ $2.58 Million	RM11.67 Million ≈ $2.93 Million	1.137x	+2735.15%
2019-06-30	RM15.93 Million ≈ $4.00 Million	RM-687.64K ≈ $-172.64K	-0.043x	+86.54%
2018-06-30	RM19.77 Million ≈ $4.96 Million	RM-6.34 Million ≈ $-1.59 Million	-0.321x	-312.09%
2017-06-30	RM24.30 Million ≈ $6.10 Million	RM3.67 Million ≈ $922.57K	0.151x	-20.39%
2016-06-30	RM19.39 Million ≈ $4.87 Million	RM3.68 Million ≈ $924.53K	0.190x	+746.88%
2015-06-30	RM17.65 Million ≈ $4.43 Million	RM395.83K ≈ $99.38K	0.022x	--

About Malaysian Genomics Resource

KLSE:0155 Malaysia Diagnostics & Research

Market Cap

$12.13 Million

RM48.30 Million MYR

Market Cap Rank

#26484 Global

#795 in Malaysia

Share Price

RM0.32

Change (1 day)

-4.48%

52-Week Range

RM0.17 - RM0.38

All Time High

RM2.72